Clinical Trial Update: A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a new formulation of Rebif (interferon-beta-1a) for relapsing-remitting multiple sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2010-07-05